Drugs / Crenolanib
Crenolanib
also known as
CP-868,596 · CP-868,596-26 · crenolanib besylate · 596-26 · ARO 002 · ARO-002-26 · CP-868 · Crenolanib besilate
Small molecule targets FLT3, PDGFRA via inhibition
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03193918 | Apr 2017 → Jul 2020 | gastroesophageal adenocarcinoma | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02270788 | Apr 2015 → Oct 2016 | acute myeloid leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01393912 | Jul 2011 → Sep 2014 | diffuse intrinsic pontine glioma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00949624 | Dec 2005 → Jun 2008 | cancer | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02626338 | Feb 2016 → Feb 2018 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02400281 | Sep 2015 → Jul 2020 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT03324243 | Jan 2018 → Dec 2020 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02626364 | Apr 2016 → Jul 2020 | glioblastoma | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02400255 | Sep 2015 → May 2022 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02283177 | Jan 2015 → Dec 2019 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01657682 | Oct 2012 → Apr 2019 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01522469 | Jul 2012 → Aug 2014 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01243346 | Apr 2011 → Jul 2014 | gastrointestinal stromal tumor | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01229644 | Apr 2011 → Jun 2012 | glioma | Arog Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00386555 | May 2007 → ? | non-small cell lung carcinoma | Arog Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 34 trials | ||||||
| Phase 3 | NCT03250338 | Aug 2018 → Apr 2026 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03258931 | Aug 2018 → Apr 2026 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02298166 | Nov 2016 → Mar 2020 | acute myeloid leukemia | University of Ulm | Terminated | No outcome recorded |
| Phase 3 | NCT02847429 | Aug 2016 → Aug 2021 | gastrointestinal stromal tumor | Arog Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03620318 | — | acute myeloid leukemia, FLT3 internal tandem duplication, acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation | Arog Pharmaceuticals, Inc. | Available | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crenolanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02400255 ↗ |
| Known as | 596-26 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105728 ↗ |
| Known as | ARO 002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105728 ↗ |
| Known as | ARO-002-26 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105728 ↗ |
| Known as | CP-868 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105728 ↗ |
| Known as | CP-868,596 | “Crenolanib (CP-868,596) is an orally bioavailable, selective inhibitor of PDGFR receptor tyrosine kinase with IC50s of 0.4 ng/mL and 0.8 ng/mL for PDGFRα and PDGFRβ, respectively.” NCT01243346 ↗3“A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas” NCT01229644 ↗ |
| Known as | CP-868,596-26 | “Crenolanib besylate (CP-868,596-26), Dose: 140mg BID” NCT01243346 ↗1“Crenolanib Besylate (CP-868,596-26)” NCT01522469 ↗ |
| Known as | Crenolanib besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105728 ↗ |
| Known as | crenolanib besylate | “This is a Phase II open label study of crenolanib besylate.” NCT01522469 ↗1“Crenolanib besylate (CP-868,596-26), Dose: 140mg BID” NCT01243346 ↗ |
| Action | Inhibit | “CP-868,596 is a platelet-derived growth factor receptor inhibitor (PDGFR)” NCT00949624 ↗ |
| Modality | Small molecule | “Crenolanib is a highly selective and potent FLT3 tyrosine kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) mutants and the FLT3/D835...” PMID 24227820 ↗ Nov 2013 |
| Route | Oral | “Oral tablet 60 mg BID continuous” NCT00949624 ↗ |
| Target | PDGFRA | “In preclinical models of cell lines with the D842V mutation in the PDGFRA gene, crenolanib (CP-868,596) blocked phosphorylation of PDGFRα at nanomolar concentrations” NCT01243346 ↗ |